Latest Breaking News On - Kalvista pharmaceuticals - Page 1 : comparemela.com

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomHenriette farkasBen palleikoPaul audhyaEuropean medicines agencyKalvista pharmaceuticals incEuropean academy of allergyDrug administrationSemmelweis universityHungarian angioedema centerDepartment of internal medicineExchange commissionClinical immunology congressKalvista pharmaceuticalsEuropean academyNew england journal

KalVista Pharmaceuticals, Inc : KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

KalVista Pharmaceuticals, Inc : KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomPaul audhyaJarrod aldomBryan bakerBen palleikoHenriette farkasEuropean academy of allergySemmelweis universityKalvista pharmaceuticals incDepartment of internal medicineExchange commissionClinical immunology congressHungarian angioedema centerCorporate communicationsDrug administrationEuropean medicines agency

KalVista Pharmaceuticals, Inc (NASDAQ:KALV) Insider Edward P Feener Sells 8,088 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) insider Edward P. Feener sold 8,088 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $11.76, for a total value of $95,114.88. Following the sale, the insider now directly owns 72,858 shares in […]

United statesEdwardp feenerKalvista pharmaceuticalsEntrypoint capitalInstitutional trading of kalvista pharmaceuticalsChina universal asset management coTower research capitalNeedham companyQuarter for kalvista pharmaceuticalsKalvista pharmaceuticals incKalvista pharmaceuticals stock performanceNews ratings for kalvista pharmaceuticals dailyGet free reportVista pharmaceuticalsResearch capitalUniversal asset management

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its.

United kingdomKalvista pharmaceuticals incExchange commissionGenetic medicines forumDrug administrationKalvista pharmaceuticalsGlobal healthcare conferenceNew yorkVista pharmaceuticalsSecurities litigation reform act

AJOVista LLC Acquires Shares of 4,920 KalVista Pharmaceuticals, Inc (NASDAQ:KALV)

AJOVista LLC Acquires Shares of 4,920 KalVista Pharmaceuticals, Inc (NASDAQ:KALV)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkBenjaminl palleikoKalvista pharmaceuticals incNeedham companyKalvista pharmaceuticals company profileQuarter for kalvista pharmaceuticalsChina universal asset management coSecurities exchange commissionKalvista pharmaceuticals stock downInsider transactions at kalvista pharmaceuticalsKalvista pharmaceuticalsPrincipal financial group incYork state common retirement fundExchange commissionNews ratings for kalvista pharmaceuticals daily